US$ 28.64
bpc-157 for ketamine BPC 157 Peptide Therapy BPC-157 and the gut–brain axis:
Description
Obesity classification

Individuals considering BPC-157 should proceed with caution and consult healthcare professionals about the potential risks and benefits, especially given the current lack of regulatory approval and the limited data on human applications

Bevacizumab, a monoclonal antibody targeting VEGF, is categorised as FDA Pregnancy Category C (risk cannot be ruled out) based on animal studies showing embryo-foetal toxicity

High concentrations can cause scale to form or lead to corrosion, resulting in system inefficiencies, failures and maintenance headaches
